Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

Recommendation ID: CG164/4
Question: Chemoprevention to reduce incidence of breast cancer:- A randomised controlled trial is recommended to compare the clinical and cost effectiveness of aromatase inhibitors and tamoxifen for reducing the incidence of breast cancer in women with a family history of breast or ovarian cancer. [new 2013]
Any explanatory notes (if applicable): Why this is important:- This guideline recommends offering raloxifene or tamoxifen to women at high risk of developing breast cancer and considering such treatments as chemoprevention for women at moderate risk. One randomised study in North America showed an aromatase inhibitor (exemestane) to be effective for the primary prevention of breast cancer. However, there has been no randomised control trial comparing aromatase inhibitors with tamoxifen or raloxifene (selective oestrogen receptor modulators or SERMs). Such a trial could better inform women of the best available approach for the chemoprevention of breast cancer.

Source guidance details

Comes from guidance: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
Number: CG164
Date issued: June 2013

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	12/07/2013